Similar articles

• Biotech parks proliferate, despite concerns over sustainability.

  Jia H, Jayaraman KS, Orellana C. Jia H, et al. Nat Biotechnol. 2003 Nov;21(11):1259-60. doi: 10.1038/nbt900. Nat Biotechnol. 2003. PMID: 14595344 No abstract available.
• Benefits of biotech clusters questioned.

  Sheridan C. Sheridan C. Nat Biotechnol. 2003 Nov;21(11):1258-9. doi: 10.1038/nbt902. Nat Biotechnol. 2003. PMID: 14595343 No abstract available.
• Earlier stage biotechs attract partners.

  Ratner M. Ratner M. Nat Biotechnol. 2005 May;23(5):509. doi: 10.1038/nbt0505-509. Nat Biotechnol. 2005. PMID: 15877052 No abstract available.
• The case for entrepreneurship in R&D in the pharmaceutical industry.

  Douglas FL, Narayanan VK, Mitchell L, Litan RE. Douglas FL, et al. Nat Rev Drug Discov. 2010 Sep;9(9):683-9. doi: 10.1038/nrd3230. Epub 2010 Aug 20. Nat Rev Drug Discov. 2010. PMID: 20725093 Review.
• Cenamps: adding value to the North East region.

  Maw A, Pitkethly M, Gohir S, McMurray A, Robbins D. Maw A, et al. Nanomedicine (Lond). 2006 Dec;1(4):499-504. doi: 10.2217/17435889.1.4.499. Nanomedicine (Lond). 2006. PMID: 17716155 Review.